5-MAPB

Discovery and market emergence

5-MAPB entered the research chemical market around 2011–2012 alongside related benzofuran compounds 5-APB, 6-APB, and 6-MAPB. Sold collectively as "benzofury," these were gray-market alternatives to MDMA targeting online vendors and the United Kingdom club scene. No original discoverer or primary synthesis paper has been identified in the peer-reviewed literature.citation needed

Research characterization

The first in vitro pharmacological characterization appeared in 2015, when Rickli et al. established monoamine transporter interaction profiles and serotonin receptor activity for the benzofuran class.^[3] That same year, Welter et al. described metabolism in rat models and confirmed the compound's presence in human clinical plasma samples.^[1] Subsequent receptor binding studies positioned 5-MAPB and its relatives as potential second-generation entactogens for PTSD research,^[4] highlighting the overlap between academic drug discovery and the novel psychoactive substance market.

Regulatory response and modern status

The United Kingdom was the first major jurisdiction to act, issuing a Temporary Class Drug Order in 2013 covering the benzofuran class,^[8] followed by permanent Class B scheduling in 2014.^[9] Germany's NpSG brought benzofurans under control in 2016. Academic interest continues through behavioral pharmacology confirming MDMA-like properties^[10] and medicinal chemistry programs using 5-MAPB as a reference entactogen,^[11] but no clinical trial has been initiated.

Structural class

5-MAPB belongs to the aminoalkylbenzofuran series — compounds in which MDMA's methylenedioxy ring is replaced by a benzofuran system (an oxygen-containing fused bicyclic ring). This bioisosteric swap preserves monoamine releasing activity while changing receptor selectivity and metabolic stability.^[12]

Within the series, 5-MAPB is the N-methyl derivative of 5-APB, paralleling the amphetamine-to-methamphetamine relationship.^[1] The "5-" prefix indicates substitution at the 5-position of the benzofuran ring; the 6-position isomers (6-APB, 6-MAPB) have distinct pharmacological profiles.

Molecular properties

The molecule consists of a benzofuran ring system bearing a 2-aminopropyl chain at C-5, with an N-methyl group on the amine nitrogen. The hydrochloride salt (C₁₂H₁₅NO·HCl) is the most commonly encountered form on the research chemical market.

Stereochemistry

5-MAPB has a chirality center at C-2 of the propylamine side chain, producing R- and S-enantiomers. No enantioselective pharmacological data specific to 5-MAPB have been published. In the related compound 5-MABB, S-isomers retain full releasing activity at all three monoamine transporters while R-isomers lack dopamine releasing activity^[11] — a pattern that may extend to 5-MAPB but remains unconfirmed.

Mechanism of action

5-MAPB enters monoamine transporters as a false substrate and reverses their direction, causing serotonin, dopamine, and norepinephrine to flood the synaptic cleft.^[3] This mechanism is identical to MDMA: the compound hijacks the reuptake machinery and turns it into a release machine.

5-MAPB is roughly two to three times more potent than MDA at all three monoamine transporters.^[2] Its release profile is more balanced than MDMA's — less serotonin-dominant, with comparatively stronger dopamine and norepinephrine contributions. This pharmacological signature predicts an entactogenic experience with more stimulant drive and euphoria than MDMA.

Beyond transporter-mediated release, 5-MAPB directly activates serotonin receptors, notably 5-HT₂B and 5-HT₂C.^[4] The 5-HT₂B activity is clinically concerning: chronic activation of this receptor causes heart valve thickening, a mechanism established through the fenfluramine precedent.^[3]

A preliminary finding of potent MAO-A inhibition^[4] carries major safety implications if confirmed. Combined monoamine release and monoamine oxidase inhibition would create a self-potentiating serotonergic effect, raising baseline serotonin syndrome risk above that of MDMA.

Pharmacokinetics

No controlled human pharmacokinetic study has been published. Half-life, bioavailability, and peak plasma time are unknown.

The primary metabolic pathway proceeds via N-demethylation to the active metabolite 5-APB, followed by ring hydroxylation and oxidative ring-opening.^[1] CYP2B6 handles the majority of metabolic clearance,^[1] meaning individuals with genetic variants affecting CYP2B6 activity may experience altered drug exposure.

In six clinical cases, plasma concentrations ranged from 5–124 μg/L for 5-MAPB and 1–38 μg/L for the 5-APB metabolite.^[1] These data confirm oral bioavailability and active metabolite formation in humans. Because 5-APB is itself pharmacologically active, subjective effects may extend beyond the parent compound's clearance.

Where it acts

5-MAPB's simultaneous release of serotonin, dopamine, and norepinephrine produces a neural signature characteristic of the entactogen class: reduced threat reactivity in the amygdala, strengthened prefrontal-amygdala communication, and downstream oxytocin release.^[3][10] This pattern underlies the emotional openness and reduced social anxiety that define the experience.

The relatively stronger dopaminergic contribution compared to MDMA^[2] predicts greater activation of the brain's reward circuitry, which may account for the more pronounced euphoria and the stronger redosing urge reported by users. Norepinephrine release drives the stimulant dimension — elevated heart rate, alertness, and peripheral vasoconstriction.^[4]

Why it matters

Entactogens are theorized to open a neurochemical window for therapeutic memory reconsolidation — the process by which recalled emotional memories become modifiable before re-storage. The combination of dampened fear response, enhanced prefrontal regulation, and elevated social trust creates conditions under which traumatic memories can be processed without overwhelming distress.^[4]

This mechanism underlies the rationale for examining benzofurans as potential PTSD therapeutics. Direct 5-HT₂C agonism^[4] adds a receptor-mediated mood-modulating component beyond transporter release, while the relative weakness at 5-HT₂A may explain why 5-MAPB produces less perceptual distortion than 5-APB or MDA.

Toxicity

No lethal dose has been established for 5-MAPB in any species, and no human death has been attributed to 5-MAPB alone. The single published fatality involved polydrug co-intoxication with AMT, benzodiazepines, and sympathomimetic agents.^[6] Non-fatal clinical cases showed plasma concentrations of 5–124 μg/L without reported organ damage,^[1] though systematic follow-up data are absent.

Chronic cardiac risk: Repeated exposure raises theoretical concern for heart valve thickening through serotonin₂B receptor activation — the same mechanism that caused valve disease in fenfluramine users.^[3] No cases have been documented for 5-MAPB, but no long-term studies have looked.

Psychological risks

Acute psychological distress — anxiety, agitation, paranoia — may occur at high doses or in adverse settings. Post-use mood disruption (depression, irritability, mental fatigue) is expected from the monoamine depletion that follows the acute serotonin and dopamine surge.^[13] Severity is dose-dependent and worsened by repeated dosing within a single session.

Psychosis has been reported in case series involving novel psychoactive stimulant/entactogen use, typically in the context of polydrug use or pre-existing psychiatric vulnerability.^[14]

Compulsive redosing is a recognized behavioral risk. The strong dopamine releasing activity^[2] engages reward circuitry sufficient to drive re-administration urges, particularly as the serotonergic effects fade and the dopaminergic "wanting" signal persists.

Tolerance and dependence

No substance-specific tolerance or dependence data exist for 5-MAPB.

Tolerance develops with repeated use through SERT downregulation and monoamine depletion, consistent with the MDMA class pattern.inferred Cross-tolerance with other serotonergic and dopaminergic releasers (including MDMA, MDA, and amphetamines) is expected based on shared mechanisms.

Dependence: 5-MAPB fully substitutes for MDMA in drug discrimination studies at more potent doses,^[10] confirming abuse potential. The strong dopamine releasing activity^[2] predicts engagement of reward circuitry sufficient to support psychological dependence. No human dependence case reports have been published. Physical dependence liability is expected to be low based on MDMA class patterns.

Drug interactions

As a potent serotonin releaser, 5-MAPB creates dangerous additive risk when combined with any drug that raises serotonin levels. The combination with MAO inhibitors is the highest-risk interaction: deaths from MDMA combined with moclobemide are documented,^[7][15] and the same mechanism applies to 5-MAPB. If 5-MAPB itself inhibits MAO-A as preliminary data suggest,^[4] co-administration with an external MAOI could produce catastrophic serotonin accumulation.

Tramadol carries high serotonin syndrome risk due to its own serotonin-raising activity combined with 5-MAPB's releasing mechanism.safety citation needed

SSRIs and SNRIs may both blunt desired effects and paradoxically increase serotonin syndrome risk through combined serotonergic load.

Lithium augments serotonin signaling and may lower the threshold for serotonin toxicity.safety citation needed

Co-administration with other stimulants (MDMA, amphetamines, cocaine, ephedrine) produces additive cardiovascular strain. The fatal polydrug case included ephedrine alongside AMT and 5-MAPB.^[6]

CYP2B6 inhibitors (ticlopidine, clopidogrel) could increase 5-MAPB levels by slowing metabolic clearance. CYP2B6 inducers (rifampicin, carbamazepine) could reduce levels and shift the metabolite ratio.^[1]

Contraindications

Absolute contraindications

• Concurrent MAO inhibitor use — irreversible (phenelzine, tranylcypromine) or reversible (moclobemide). Fatal serotonin syndrome risk.^[7][15]
• Concurrent serotonergic agent use (tramadol, SSRIs, SNRIs, other serotonin releasers) — elevated serotonin syndrome risk.

Relative contraindications

• Heart conditions — the sympathomimetic mechanism poses risk to individuals with pre-existing cardiac disease, high blood pressure, or irregular heartbeat.
• Liver impairment — CYP2B6-dependent metabolism means impaired liver function could increase drug exposure.
• Psychiatric vulnerability — personal or family history of psychotic disorders, bipolar disorder, or severe anxiety disorders.
• Pregnancy and breastfeeding — no reproductive toxicity data exist; contraindicated based on class-level risk.safety citation needed
• CYP2B6/CYP2D6 poor metabolizer status — elevated plasma exposure and altered metabolite ratios.^[1]

5-MAPB occupies a variable legal position internationally. It is explicitly controlled in the United Kingdom and Germany under class-wide legislation targeting the aminoalkylbenzofuran scaffold. In the United States, it is not individually scheduled but falls within the scope of the Federal Analogue Act when intended for human consumption. Scheduling across other jurisdictions is inconsistent, reflecting the compound's status as a novel psychoactive substance that predates harmonized international control frameworks.

Analog act considerations

In jurisdictions with analog legislation (notably the United States), 5-MAPB's structural similarity to MDMA (Schedule I) and MDA (Schedule I) — confirmed by identical monoamine releasing mechanism^[3] and full MDMA substitution in drug discrimination^[10] — provides the basis for prosecution under the Federal Analogue Act. The bioisosteric relationship (benzofuran replacing methylenedioxy ring) is a straightforward structural argument. Prosecution outcomes depend on case-specific factors including intent of use and expert testimony on pharmacological similarity.